Abstract 336P
Background
CIPN is a dose-limiting and disabling side effect of oxaliplatin and/or paclitaxel. We prospectively evaluated the efficacy of methylcobalamin administered intravenously for CIPN.
Methods
Thirty patients with gastrointestinal cancer who were receiving oxaliplatin and/or paclitaxel and had peripheral neuropathy of CTCAE ≥ 2 were enrolled to the trial. Each patient recieving chemotherapy containing oxaliplatin and/or paclitaxel and devoloping CIPN>Grade 1 was assessed CIPN on day 3 and (T1) a day before the next cycle (T2) with Chemotherapy-Induced Peripheral Neuropathy Assessment Tool (CIPNAT) for two cycles. Methylcobalamin intramuscularly was used for the first cycle and intravenously for the second cycle in the first 15 patients. Injection order was reversed in the latter 15 patients. Methylcobalamin 5 mg/d was given from day 3 to a day before the next cycle. The primary end point was a change of CIPNAT score between T1 and T2.
Results
Thirty patients were enrolled and completed the trial. Median age was 62 (range, 31- 76), male/female was 20/10. Most primary sites were gastric cancer (n=13), colorectal cancer (n=12). Most regimens were paclitaxel/oxaliplatin/5-FU (n=13), FOLFOXIRI (n=11), FOLFOX (n=3), paclitaxel/5-FU (n=2), nab-paclitaxel (n=1). The mean number of cycles of chemotherapy before the start of methylcobalamin injection was 6 (1-12). The total CIPNAT scores (mean±SD) were 148.90±56.09 for T1, 41.40±37.52 for T2 in the intravenous cycle, 158.90±57.02 for T1, 120.20±56.02 for T2 in the intramuscular cycle. A decline in CIPNAT score (mean±SD) between T1 and T2 was 107.50±42.04 in the intravenous cycle, and 38.70±30.33 in the intramuscular cycle (Z=5.715, P<0.001). No significant drug and injection-related side effects were observed in both groups.
Conclusions
Intravenous methylcobalamin is more effective than intramuscular injection in oxaliplatin and/or paclitaxel-induced peripheral neurotoxicity.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Rongbo Lin.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
104P - Safety and efficacy of HLX04 versus reference bevacizumab in combination with XELOX or mFOLFOX6 as first-line treatment for metastatic colorectal cancer: A randomised, double-blind phase III study
Presenter: Shukui Qin
Session: e-Poster Display Session
105P - Prospective, open-label, observational study of cetuximab for metastatic colorectal carcinoma (mCRC): The OPTIM1SE study
Presenter: Tsai-Sheng Yang
Session: e-Poster Display Session
106P - Efficacy and tolerability of capecitabine and mitomycin-C based concurrent radiotherapy in patients with anal canal cancer
Presenter: Prabhat Bhargava
Session: e-Poster Display Session
107P - Safety and efficacy of trifluridine/tipiracil (FTD/TPI) in previously treated metastatic colorectal cancer (mCRC): Results from the Australian cohort of the phase IIIb, international, open-label, early-access PRECONNECT study
Presenter: Timothy Price
Session: e-Poster Display Session
108P - Comparative analysis of two-stage hepatectomy and enhanced one-stage hepatectomy in the setting of bilobar colorectal liver metastases
Presenter: Hayk Torgomyan
Session: e-Poster Display Session
109P - Efficacy and safety of biweekly or triweekly XELOX regimen for adjuvant chemotherapy of colorectal cancer
Presenter: hangyu zhang
Session: e-Poster Display Session
110P - Analysis for stereotactic body radiotherapy (SBRT) effect for colorectal liver metastases
Presenter: Wei Zou
Session: e-Poster Display Session
111P - A meta-analysis study on safety and effectiveness comparison between FOLFOX and XELOX regiments on advanced stage colorectal cancer
Presenter: Ida Bagus Budhi
Session: e-Poster Display Session
112P - Pembrolizumab vs chemotherapy in patients with microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: Asia subgroup results of the phase III KEYNOTE-177 study
Presenter: Takayuki Yoshino
Session: e-Poster Display Session
122P - Nomogram to predict short-term effect of radiotherapy based on pre/post-treatment inflammatory biomarkers and their dynamic changes in esophageal squamous cell carcinoma
Presenter: Shuai Liang
Session: e-Poster Display Session